The Adolescent Breast

Donald E. Greydanus
Michigan State University

Stephanie Stockburger
University of Kentucky, stephanie.stockburger@uky.edu

Hatim A. Omar
University of Kentucky, hatim.omar@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/pediatrics_facpub

Part of the Pediatrics Commons
Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation
Greydanus, Donald E.; Stockburger, Stephanie; and Omar, Hatim A., "The Adolescent Breast" (2012).
Pediatrics Faculty Publications. 103.
https://uknowledge.uky.edu/pediatrics_facpub/103

This Book Chapter is brought to you for free and open access by the Pediatrics at UKnowledge. It has been accepted for inclusion in Pediatrics Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
The Adolescent Breast

Notes/Citation Information

©2012 Walter de Greyter GmbH & Co. KG, Berlin, Boston

The copyright holder has granted permission for posting the chapter here.


16 The adolescent breast

Donald E. Greydanus, Stephanie Stockburger, and Hatim A. Omar

The breast is an important organ system for the adolescent female and occasionally for the adolescent male as well. This chapter reviews basic principles of breast concerns and disorders including congenital anomalies, asymmetric breast development, underdeveloped breasts, virginal hypertrophy, breast masses, mastalgia, galactorrhea, gynecomastia in males, and others. Clinicians should be attuned to issues and concerns for this important structure in adolescents.

16.1 Introduction

The breast is a modified sweat gland that is enveloped by layers (superficial and deep) of the superficial fascia in the thorax; this organ system is suspended from the chest wall by Cooper’s ligaments (fibrous septae) that extend from the pectoralis fascia to the dermis. Estrogen, progesterone, and prolactin are hormones that are important in breast development as reviewed in Tab. 16.1. Additional key hormones include thyroxine, insulin, growth hormone, and adrenal corticoids.

16.2 Clinician’s breast examination

Though often neglected by clinicians, breast examination remains an important aspect of the physical examination process in adolescents (1,2,3,4,5). Though rare in adolescents, breast pain and/or a breast lump stimulate fears of breast cancer in the youth and her parents. The clinician should not ignore this system, but learn to minimize embarrassment in the exam process and help the adolescent understand her body as well as possible. During the adolescent years, she can be taught about breast self-examination as a way of reducing her breast cancer risk as she reaches adulthood. Regular self-examinations should be developed by age 20 years.

A careful history is important and includes asking about age, when the breast buds developed (Tanner 2 or sexual maturity rating 2) and breast growth rate as well as the possible presence of nipple discharge, lesions, and pain. A menstrual history is also important to obtain. The female may be concerned about the size of her breasts, possible asymmetry, or the timing of the growth of her breasts (precocious or delayed). While the youth may not vocalize concerns, it is important to emphasize the normalcy of her breasts, if appropriate.
Tab. 16.1: Impact of hormones on breast development.

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen</td>
<td>Ductal system growth, Nipple maturation, Areolar development (increased pigmentation and size), Induction of periductal fibrous tissue growth</td>
</tr>
<tr>
<td>Progesterone</td>
<td>Alveolar maturation</td>
</tr>
<tr>
<td>Prolactin</td>
<td>Maturation resulting in lactation</td>
</tr>
</tbody>
</table>

16.3 Congenital anomalies

16.3.1 Athelia and amastia

The absence of a nipple (athelia) is a rare congenital anomaly resulting from the impact of taking exogenous androgen during pregnancy (6,7). Another rare anomaly is absence of a breast (amastia), caused by mammary ridge involution involving the pectoral ridge on the affected side. Amastia is typically unilateral and in association with defects of the chest wall. Poland syndrome is characterized by unilateral amastia with no pectoralis muscle development, defects of the ribs, radial nerve palsy, and webbing of the fingers. Amastia can be acquired after birth from inadvertent breast bed biopsy, radiation damage to the breast, or other injury. Treatment involves surgical correction of abnormalities.

16.3.2 Polythelia and polymastia

Extra accessory nipples (polythelia) and accessory breast tissue (polymastia or supernumerary breasts) are more common congenital breast anomalies found along the milk lines from the axilla to the groin. A variety of nipple, areola, and glandular tissue combinations can be found. Polythelia (involving nipple and areola) is noted in 1–2 percent of the general population and may be associated with cardiovascular and genitourinary defects. The extra nipple tissue may erroneously be called a mole, while the extra breast tissue can be mistaken for hidradenitis suppurativa. Management involves surgical removal if the patient is concerned about cosmetic appearance.

16.3.3 Other nipple anomalies

A nipple that does not extend beyond the breast surface is called an inverted nipple; it is often bilateral and normally corrects itself within a few weeks after birth. If still noted after puberty, concerns about its appearance, frequent infection, and/or lactation problems may surface in the youth. Congenital nipple inversion can lead to chronic areolar abscess, characterized by nipple swelling, pain, and discharge along with periareolar erythema. Treatment involves local heat, antibiotics, and surgery in some cases to remove the duct system.

Acute retraction of a nipple may suggest breast disease, such as breast cancer. Fortunately, this is rare in the adolescent. Other defects include a depressed nipple (with lactiferous ducts opening into a depressed area in the areolar center) and a bifid or split nipple. Depressed, bifid, or split nipple may also be managed surgically.
16.4 Asymmetric breast development

Breast asymmetry develops in many female adolescents, often improves as puberty progresses, and is noted in about 25 percent of adult females (8). It usually is a normal variant of breast growth with the smaller breast typically opposite to the dominant hand. A padded bra and reassurance is all that is needed in most cases. Once the breast development is complete on both sides, surgical correction of the asymmetry can be considered if desired and affordable.

In adolescence, as one breast bud develops before the other, the young adolescent may present with a unilateral mass sometimes mistaken for a tumor. Biopsy of this “lesion” results in damage to the yet-to-mature breast and should be avoided. Damage to a breast bud can also result from injury to this area from infection, burns, anterolateral thoracotomy, and thoracostomy tube insertions in childhood. Burns to the chest area usually cause skin contractures with underlying breast tissue that is normal; release of these contractures in the early teen years allow normal growth of the adolescent breast. Also, scoliosis or defects of the rib cage can result in the appearance of breast asymmetry, or pseudoasymmetry.

16.5 Underdeveloped breasts

A common concern among adolescent females is that of small breasts (micromastia), or breasts that are much smaller than what they or society feels are normal. It is often a familial condition and may be noted in those with a tall, thin body type with limited subcutaneous tissue in general and sometimes who have connective tissue disorders. Reassurance of the normalcy of the breasts is important and that the “small” breasts need not interfere with her sense of femininity, sexual relations, pregnancy, or lactation. Augmentation mammoplasty can be done at some time in her life when she is emotionally, cognitively, and financially ready for such surgery.

Unilateral or bilateral hypoplasia of the breasts may be difficult to distinguish from micromastia. Hypoplasia or hypomastia may be due to partial end-organ response failure, in which the breast(s) do not develop into normal breasts. Bilateral hypoplasia may result from androgen excess in utero or in early infant life; this may be due to congenital adrenal hyperplasia, leading to the prevention of ovarian maturation and estrogen secretion during puberty. The nipples are smaller, less pigmented, less estrogenized, and do not have papillae that are protuberant. The public hair may develop without thelarche, and menarche may be delayed. A careful genetic and endocrinologic evaluation is necessary for bilateral hypoplasia. Causes include gonadal dysgenesis (Turner syndrome), androgen-producing tumor, preadolescent hypothyroidism, and gonadotropin deficiency (pituitary hypogonadism). Poor or limited breast development may also result from radiation and bilateral ovariectomy.

Breast atrophy

Atrophy of the breasts results from significant weight loss and hypoestrogenemia, as noted in anorexia nervosa, chronic illness, postpartum depression, crash dieting, and other conditions. The result is loss of breast adipose tissue and, often, severe acquired
breast atrophy. Scleroderma can cause local breast changes, while premature ovarian failure can induce secondary amenorrhea and breast atrophy. The breasts become wrinkled, flattened, and old in appearance. Treatment of breast atrophy is to correct the underlying problem.

16.5.1 Tuberous breasts

In this rare breast anomaly, the shape of the breasts is abnormal in which the tuberous breasts project forward without normal fullness; the areolar complex is overdeveloped, with the appearance of herniation of breast tissue into the areola. Surgical correction is necessary to improve the breast appearance by reconstructing the nipple-areolar complex along with breast augmentation.

16.6 Virginal hypertrophy

Thelarche in some females leads to massive diffuse enlargement of breasts to such an extent that it is termed juvenile, virginal, or idiopathic breast hypertrophy; even more massive development is called macromastia or gigantomastia (9). The cause is usually linked to individual variation, familial factors, sensitivity to estrogen and/or abnormal estrogen-progesterone ratio, and endogenous production of estrogen within breast cells. Obesity may play a role in some youth. Unilateral hypertrophy may also be seen and can be caused by a breast neoplasm (such as a giant fibroadenoma – see section 16.7). Breasts may develop superficial changes including prominent superficial veins and possibly skin necrosis. The nipple and areola may be stretched so that they are difficult to distinguish. Complications may be worsened with a tight brassiere.

There are no medications that are acceptable to use in adolescents. Some clinicians have used danazol or medroxyprogesterone to reduced breast size; however, there is no clear research that these really help. Side effects of the medications (such as masculinization and teratogenicity) prohibit their use in youth. Surgical breast reduction is an option when the adolescent is mature enough to understand this surgery and accept potential complications. If surgery is done too early, breast enlargement may continue and negate the effects of the surgery. Breast reduction often involves reimplantation of the nipple-areolar complex, leading to potential lactation and nerve damage; the erotic potential of breast stimulation may be reduced.

16.7 Breast masses

The following box, “Causes of Breast Masses in Adolescents,” lists causes of breast masses in the adolescent; 70–90 percent of masses that are biopsied are fibroadenomas, and most of the other masses are benign cysts. Since malignancy is rare in the adolescent, observation of a mass over a few months is usually an appropriate clinical response. Breast cancer is noted in less than 2.5 percent of palpable breast masses in females under 30 and less than 0.5 percent in those under age 20 years.
### Causes of breast masses in adolescents

<table>
<thead>
<tr>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibroadenoma</td>
</tr>
<tr>
<td>Juvenile (giant) fibroadenoma</td>
</tr>
<tr>
<td>Other fibroadenoma variants</td>
</tr>
<tr>
<td>Virginal hyperplasia</td>
</tr>
<tr>
<td>Breast abscess/mastitis</td>
</tr>
<tr>
<td>Cystosarcoma phylloides</td>
</tr>
<tr>
<td>Intraductal papilloma (papillomatosis)</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Breast cysts</td>
</tr>
<tr>
<td>Fibrocystic change</td>
</tr>
<tr>
<td>Ductal adenocarcinoma</td>
</tr>
<tr>
<td>Gynecomastia</td>
</tr>
<tr>
<td>Nipple adenoma</td>
</tr>
<tr>
<td>Nipple keratoma</td>
</tr>
<tr>
<td>Fat necrosis</td>
</tr>
<tr>
<td>Lipoma</td>
</tr>
<tr>
<td>Intraductal granuloma</td>
</tr>
<tr>
<td>Hematoma</td>
</tr>
<tr>
<td>Intertitial (parenchymal) fibrosis</td>
</tr>
<tr>
<td>Mammary duct ectasia</td>
</tr>
<tr>
<td>Metastatic disease (leukemia, lymphoma, ovarian malignancy, others)</td>
</tr>
<tr>
<td>Angiosarcoma</td>
</tr>
<tr>
<td>Dermatomyofibromatosis</td>
</tr>
<tr>
<td>Hemangioma</td>
</tr>
<tr>
<td>Lymphangioma</td>
</tr>
<tr>
<td>Neurofibromatosis</td>
</tr>
<tr>
<td>Papilloma sarcoidosis</td>
</tr>
<tr>
<td>Sclerosing adenosis</td>
</tr>
<tr>
<td>Tuberos mastitis</td>
</tr>
<tr>
<td>Others</td>
</tr>
</tbody>
</table>

Important historical points in assessment of a breast mass include if there is associated pain (cyclical or noncyclical), galactorrhea, size of the lesion, and how long it has been present. An excisional biopsy is typically obtained for a mass that is hard, does not resolve, increases in size, fails to decrease over a few menstrual cycles, resumes after aspiration, and or has bloody nipple discharge.

### Fibroadenoma

Fibroadenoma is a benign tumor arising from ducts and stoma of the terminal part of the breast system (8). It is the most common lesion noted in postpubertal females up to 25 years of age. Fibroadenomas are typically well demarcated, encapsulated, round, rubbery, and nontender. They are usually single and found in the upper, outer quadrant, though any quadrant may be noted. As many as 20 percent have bilateral or multiple
tumors, in which case the condition is called fibroadenomatosis. A fibroadenoma may be 2–3 cm when first found but may enlarge at the end of a menstrual cycle and can also increase during pregnancy. The ultrasound appearance is that of a smooth margin mass that is homogeneous.

A fibroadenoma does not become malignant and does not increase the adolescent's risk for malignancy later in life. If a lesion appearing to be a fibroadenoma does not decrease over 4 to 6 months, or if it continues to enlarge, excision is usually recommended. Removal of a large mass may require more surgery to reduce the skin envelope for a cosmetic closure. If concern is raised about potential cancer, excision is also suggested.

**Giant (juvenile) fibroadenoma**

A fibroadenoma that is more than 5 cm is often defined as a giant or juvenile type and is important because it can grow quickly to a large size, doubling itself in 3 to 6 months. It tends to be seen in young adolescents, has a consistency that is softer, has more dilation of superficial veins, and can cause considerable breast distortion. Though a benign tumor, it should be excised before becoming too large.

**16.7.1 Cystosarcoma phylloides**

Cystosarcoma phylloides (phylloides tumors) is the most common malignant tumor of the breast reported in adolescents. Though a rare event in youth, the incidence is 0.3–0.8 percent of all breast tumors in adults with an incidence of metastasis of 3–12 percent; approximately 6 percent of these tumors occur in females under age 20 years. Cystosarcoma phylloides presents as a painless, multilobular tumor that is rapidly growing, nonfixed, and often 8–10 cm when first found. It often presents with nipple discharge, venous dilation, and skin discoloration. Studies note that 10–15 percent are malignant and metastases develop, particularly to the lungs. A wide excision (with 2 cm margins that are tumor free) is considered curative for benign tumors. Management of a malignant type includes surgery, radiation, chemotherapy, and hormonal treatment. Though the prognosis is poor, it is better in adolescents than in adults.

**Intraductal papilloma**

Intraductal papilloma (papillomatosis) typically presents as a painful, subareolar mass that is unilateral in three-fourths of cases. A serosanguineous or serous nipple discharge is often described on the affected side. In studies of breast masses in adolescents, an incidence of 4 percent to 6 percent and a mean age of 17 to 18 years of age at presentation are reported. In 30 percent of cases, a painful mass is not appreciated, though breast palpation may compress ducts filled with tumor that leads to nipple discharge. The differential diagnosis is listed in the following box. The evaluation may include fine-needle aspiration, breast ultrasonography, and ductography. Intraductal papilloma is typically a benign tumor, though the adolescent patient should be followed carefully for the possible development of a malignant change.
16.7 Breast masses

Differential diagnosis of intraductal papilloma
1. Intraductal papilloma
2. Papillary carcinoma
3. Nipple adenoma
4. Mammary duct ectasia
5. Fibroadenoma
6. Cystosarcoma phylloides
7. Infiltrating ductal adenocarcinoma (rare)

Mammary duct ectasia
Mammary duct ectasia (periductal mastitis) refers to a condition that presents as a painful subareolar nodule with nipple discharge, nipple retraction, sinus tracts (or fistulae), and axillary lymphadenopathy. It is usually seen in adult females at menopause who often had a history of lactation problems. It is the most common cause of acquired nipple inversion. Infection with Bacteroides sp. is seen in adolescents, leading to inflammatory changes and periductal fibrosis and destruction of the ductal wall. Management includes local excision of the sinus tract or fistula along with antibiotics.

16.7.2 Cystic breast disease
Well known, but less common in the adolescents are single or multiple cysts of benign breast disease. These cysts are typically not fixed to breast tissue, and aspiration reveals sterile fluid that is clear, brownish, or blood tinged. Cysts can be classified in various ways, and one system is listed in the following box, including normal physiological changes in breast size in adolescents with up to 50 percent size change during a menstrual cycle; these pseudolumps are normal. In the postpartum period, lactiferous ducts may become distended and become galactoceles, presenting as a subareolar mass with a yellow nipple discharge; it usually disappears with lactation, but surgical excision may become necessary.

Classification of breast cysts
1. Fibrocystic disease or change (with multiple small cysts)
2. Solitary large or “blue-domed” cysts (with bloody fluid)
3. Single single cysts
4. Galactoceles
5. Normal physiological change (“pseudolumps”)

Management of a breast cyst often involves fine-needle aspiration with cytological evaluation to identify if it is a matter of normal physiology or overt pathology. If the lesion disappears on aspiration, it is assumed to be a cyst, and the patient can be evaluated again in 2 to 3 months. If the lesion recurs or is solid, ultrasonography is obtained.
for further evaluation. Sometimes an open, excisional biopsy is necessary to identify and remove the breast lesion, if aspiration is not successful or not possible.

16.7.3 Fibrocystic change

Fibrocystic change (previously called fibrocystic disease) is noted in adolescents but is more commonly seen in adult females over age 35 years. It presents as firm, movable nodularities that are cord-like and distributed diffusely in the breasts. Some females develop “lumpy” breasts in their young adult years that may develop into overt fibrocystic change in later adult life. Typically, there is breast tenderness before menstruation and change in breast size during the menstrual cycle. Sometimes, noncyclical pain and size change may be noted. Biopsy may be necessary to identify the actual pathology.

Management includes good brassiere support and heat. Ibuprofen may be helpful for adolescents. Oral contraceptives may offer pain relief by inhibiting progesterone secretion, as cysts tend to be more painful in the secretory or progestational part of the menstrual cycle. Though recommended by some clinicians, there is no clear research support for the use of vitamin E, alpha-tocopherol (600 IU/day), and dietary limitations of methylxanthines (caffeine and other substances). Danazol, bromocriptine, and tamoxifen have been tried in adults but have no clear indication in adolescents.

Breast abscess

A breast abscess presents as a painful, cystic lesion with erythema that is raised and often indurated; there may also be mastitis (10). One or multiple abscess may be noted along with fever, cellulitis, and regional lymphadenopathy. Causes of breast abscess include squeezing acne lesions, areolar hair plucking, lactation, trauma (including sexual), epidermal cyst, and chronic illness with reduced host defenses. The most common bacterial causes include Staphylococcus aureus and Streptococcus though Escherichia coliPseudomonas, and other gram-negative organisms have also been noted. Blood cultures should be obtained in hospitalized patients.

Management includes heat with warm compresses, analgesics, incision, and drainage. Antibiotics are given seeking to cover most likely organisms and often include amoxicillin-clavulanate potassium or various cephalosporins. Antibiotic regimen should provide antistaphylococcal coverage. In more severe infections, antibiotics should be given parenterally. There is a 50 percent recurrence rate for infections that are delayed or only partially treated. Residual scarring may develop if there is underlying trauma and be mistaken for a tumor. A subareolar abscess can result in scarring that leads to an inverted nipple. If lactational mastitis develops, breast feeding is usually not stopped unless overt purulent nipple discharge develops.

Mastodynia

Mastodynia (mastalgia) refers to breast pain, often a hormonally induced process that is cyclical and associated with physiological changes characterized by nodularities and swellings. Menstrually induced mastodynia may be due to deficient activity of the corpus luteum producing a relative hyperestrionism. Breast trauma (the adolescent patient
may have forgotten an inciting incident), hypertrophy, and infection can cause breast pain. Breast pain may also be a side effect of oral contraceptives. Other medications that can induce painful breast enlargement include phenothiazines, reserpine, exogenous hormones, and possibly, marijuana. The differential diagnosis of mastodynia includes costochondritis, cardiac disease, and cervical spine pathology.

Management of mastodynia includes heat, good bra support, and analgesics (including the nonsteroidal anti-inflammatory agents ibuprofen or naproxen sodium) (11). If exogenous estrogen is an underlying cause, stop this medication. If the pain is severe and not related to estrogen administration, cycling the menstrual periods with oral contraceptives may be helpful. Some clinicians prescribe vitamin E (alpha-tocopherol), though actual benefit in this situation is not proved. Other unproven measures used in adult females with mastodynia are evening primrose oil and the avoidance of methylxanthines (found in cola, tea, or coffee), chocolate, nicotine, stress, and dairy products.

Additional pharmacotherapeutics include danazol, bromocriptine, and tamoxifen. Danazol is an androgen steroid and used by some clinicians to manage severe breast pain in adult females; it is not recommended in adolescents because it is not proved to help. Danazol has significant side effects, such as potential masculinization and teratogenicity. Also tried in adult females are bromocriptine (a prolactin antagonist) and tamoxifen (competes for estrogen receptors); there is no evidence of their benefit in adolescents. If breast discomfort or pain is part of swelling and weight gain associated with the menstrual cycle, diuretics may help with the breast swelling and pain.

Mondor's disease is superficial thrombophlebitis of the thoracoepigastric vein seen with pregnancy and various types of trauma (including biopsy or breast surgery). It presents with painful cords of phlebitis palpated over the involved breast, typically in the upper, lateral breast area. It typically fully resolves in 10 to 21 days, and management includes local heat along with oral analgesics.

### 16.8 Nipple discharge

Causes of nipple discharge are listed in the following box (12). A yellow discharge is seen with normal physiological effects or a galactocele, while a clear, serous, or greenish discharge suggests a physiological cyst. If the discharge is milky, consider such causes as lactation, breast cancer, microadenoma, elevated thyroid stimulating hormone, acromegaly, or phenothiazine effects. A bloody nipple discharge may be due to cystosarcoma phylloides, papillary carcinoma, intraductal papilloma, or cystic ductal hyperplasia. A brownish nipple discharge is noted with Montgomery gland secretion or intraductal papilloma, while a purulent discharge is associated with infection.

#### Causes of nipple discharge

1. Galactorrhea
2. Areolar (Montgomery) gland secretion
3. Pregnancy or abortion
4. Breast cyst (including fibrocystic change)
5. Cystic ductal hyperplasia
Causes of nipple discharge (Continued)

6. Intraductal papillomatosis (ectasia)
7. Chronic subareolar abscess
8. Carcinoma
9. Various drug effects (as marijuana, amphetamine, or codeine)
10. Galactocele

When evaluating an adolescent with a nipple discharge, the clinician should take a careful history that includes the amount and color of the nipple discharge, associated breast abnormalities, and any history for trauma, breast manipulation, or menstrual disorders. Examine the breasts (including the nipples) carefully. A ductogram (galactograph) may be helpful. Surgery may be necessary to remove the involved areolar duct to be sure a rare malignancy is not present, such as cytosarcoma phylloides or papillary carcinoma.

Galactorrhea

Galactorrhea is breast milk secretion unrelated to pregnancy or nursing that occurs more than 1 year after nursing. The fluid may be clear, white or milky, green, or yellow; it varies in amount, and a Sudan stain reveals fat globules. Tab. 16.2 lists causes of

<table>
<thead>
<tr>
<th>Tab. 16.2: Causes of galactorrhea.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recent pregnancy terminated by spontaneous or induced abortion</td>
</tr>
<tr>
<td>Neurogenic</td>
</tr>
<tr>
<td>Chest wall disorders</td>
</tr>
<tr>
<td>Bronchiectasis and chronic bronchitis</td>
</tr>
<tr>
<td>Herpes zoster</td>
</tr>
<tr>
<td>Chronic crutch use</td>
</tr>
<tr>
<td>Thoracotomy or thoracoplasty</td>
</tr>
<tr>
<td>Burns to chest wall</td>
</tr>
<tr>
<td>Breast (nipple) manipulation or stimulation</td>
</tr>
<tr>
<td>Chronic inflammatory disease or abscess of breast</td>
</tr>
<tr>
<td>Psychogenic, including pseudocyesis and pseudonursing</td>
</tr>
<tr>
<td>Miscellaneous</td>
</tr>
<tr>
<td>Hysterectomy or uterine tumors</td>
</tr>
<tr>
<td>Laparotomy</td>
</tr>
<tr>
<td>Spinal cord disorders and surgery</td>
</tr>
<tr>
<td>Idiopathic normoprolactinemic, with or without amenorrhea</td>
</tr>
<tr>
<td>Central nervous system abnormalities</td>
</tr>
<tr>
<td>Diffuse brain disease</td>
</tr>
<tr>
<td>Coma</td>
</tr>
<tr>
<td>Pseudotumor cerebri</td>
</tr>
<tr>
<td>Encephalitis and sequelae</td>
</tr>
<tr>
<td>Uremia</td>
</tr>
<tr>
<td>Tumors, infiltrations, structural abnormalities</td>
</tr>
<tr>
<td>Neurocutaneous syndromes</td>
</tr>
<tr>
<td>Craniopharyngioma</td>
</tr>
</tbody>
</table>

(Continued)
Tab. 16.2: Causes of galactorrhea. (Continued)

Pineal tumors
Other intracranial tumors, cysts, and masses
Histiocytosis X
Sarcoidosis
Pituitary stalk section
Empty sella syndrome
Pituitary infarction and Sheehan syndrome
Hyperprolactinemia with or without prolactinoma
Other functional pituitary tumors
Hypo- and hyperthyroidism
Chronic renal disease
Adrenal tumors and hypernephromas
Cirrhosis
Nelson syndrome
Acute intermittent porphyria
Testicular and ovarian tumors
Contraceptive pills, including other estrogen or progesterone
Polycystic ovary syndrome
Starvation or refeeding (including anorexia nervosa)
Cushing’s disease
Hypogonadism

Drugs
• Phenothiazines, thioxanthenes, other major tranquilizers
• Tricyclic antidepressants
• Opiates, including codeine and heroin
• Monoamine oxidase inhibitors
• Amphetamines
• Chlordiazepoxide
• Meprobamate
• Metoclopramide
• Bromocriptine withdrawal
• Cimetidine and ranitidine
• Tamoxifen
• Verapamil
• Isoniazid
• Estrogens
• Other psychotropic drugs
• Other chemotherapy drugs (cisplatin, cytosine arabinoside, adriamycin)

galactorrhea, though the most frequent are idiopathic (benign), self-manipulation, pharmacological, prolactinoma, and hypothyroidism. A variety of medications or drugs can induce hyperprolactinemia, including those that block dopamine receptors (tricyclic antidepressants, butyrophenones, and phenothiazines), deplete dopamine (as cocaine), stimulate lactotrophs (narcotics, verapamil, and high dose estrogens), and bind to dopamine receptors in the gastrointestinal tract (metoclopramide). Galactorrhea may be induced by oral contraceptives, reserpine, spironolactone, methyltestosterone, and others. Marijuana has been implicated but is not proved as a cause.

The adolescent who presents with galactorrhea needs a careful evaluation for many causes that are possible, as noted in Table 16.2. The history should look for drug abuse, menstrual abnormality, breast stimulation, headaches, visual disturbances, thyroid disorder, and other factors. Depending on history and physical exam, checking prolactin and thyroid levels is prudent. A CT or MRI of the sella turcica may be important tests to obtain. Additional testing may be necessary depending on the precise findings.

The management depends on the underlying etiology. Underlying thyroid dysfunction or menstrual abnormality should be treated. Management of a microadenoma is often with a dopamine agonist, as bromocriptine, and if necessary, surgery. Offending drugs or medications should be stopped, as should be self-manipulation or stimulation if causative. Careful follow-up is important, and consultation with experts is suggested for severe, confusing, or cases resistant to treatment.

**Gynecomastia**

Gynecomastia is a proliferation of the glandular tissue of the male breast and can be neonatal, prepubertal, or pubertal. Transient breast development is noted in 65–70 percent of adolescent males and may be linked to transient imbalances in endogenous production of estrogen (relative excess) and testosterone (relative deficiency) with end organ sensitivity. The most common type consists of a small, tender, firm, discoid subareolar mass measuring 2 to 3 cm in diameter, which is referred to as type 1 gynecomastia, or benign adolescent hypertrophy. Type 2 gynecomastia is a more generalized glandular enlargement approximating Tanner stage 3 or even stage 4 breast development in adolescent girls.

Besides idiopathic gynecomastia, pseudogynecomastia may occur in obese adolescent males with the deposition of fat in the breast region or in youth with well-developed pectoralis muscles. If gynecomastia occurs at a time other than between Tanner 2 and 4 pubertal stages, other causes should be considered. Such causes are often classified as hypothalamic, pituitary, endocrine (hormonal), or drug induced. Hypogonadism, as seen in Klinefelter’s syndrome, must be ruled out. Klinefelter’s syndrome may present with gynecomastia and small testes. Other pituitary-gonadal endocrinopathies may also be implicated, including pituitary, adrenal, or testicular tumors. A wide variety of drugs have also been implicated including estrogens (which may be taken as “street” drugs by some gay youths) and others listed in Table 16.3.

A careful evaluation is necessary for youth with gynecomastia. The history must include drugs/medications, family history, duration of the gynecomastia, weight changes and systemic disease symptomatology. The physical examination must include Tanner staging and size of each breast, testicular exam, and abdominal and neurological exams. Height, weight, and vital signs are also important.
Tab. 16.3: Causes of gynecomastia.

1. Familial gynecomastia
2. Klinefelter’s syndrome
3. Androgen insensitivity syndrome
4. Hodgkin’s disease
5. Pituitary tumor
6. Adrenal tumor
7. Thyroid dysfunction (hypo/hyperthyroidism)
8. Miscellaneous tumors (teratoma, seminoma, Leydig-cell tumor, hepatoma, bronchogenic carcinoma, others)
9. Cirrhosis of the liver
10. Chronic glomerulonephritis
11. Male pseudohermaphroditism
12. Leukemia
13. Hemophilia
14. Traumatic paraplegia
15. Starvation (on refeeding)
16. Miscellaneous drugs
   Amphetamines
   Anabolic steroids
   Birth control pills
   Busulfan (and other chemotherapeutic agents)
   Cimetidine
   Corticosteroids
   Digitalis
   Estrogens
   Human chorionic gonadotropin
   Insulin
   Isoniazid (and other anti-tuberculosis drugs)
   Marijuana
   Methadone
   Phenothiazines
   Reserpine
   Spironolactone
   Testosterone
   Tricyclic antidepressants
   Others

Treatment of normal physiological gynecomastia consists, first, of reassuring the boy that his hormones have not gone awry and that some mysterious internal confusion has not confused his sex. Mild forms, or stage 1 gynecomastia, require nothing more. Boys who are singularly upset or bordering on homosexual panic (a not uncommon normal developmental stage in the young adolescent that is likely to be exacerbated by gynecomastia) may need additional counseling, emotional support, and possibly a medical excuse (based on some other less compromising cause) from physical education classes to avoid the overwhelming anxiety that may be encountered in the locker room.

Any gynecomastia-inducing drug that is being taken should be identified and stopped. Type 2 gynecomastia deserves surgical correction as soon as it is apparent that resolution will not occur (that is, after observation for 6 to 12 months). Hormonal therapy (as with testosterone, tamoxifen, clomiphene, or danazol) is not recommended for adolescents. Testosterone has been used for the gynecomastia seen in Klinefelter's syndrome, and antiestrogenic medications (tamoxifen and clomiphene) have been used in some adults with gynecomastia.

16.9 Summary

This chapter has reviewed important issues and disorders in the adolescent breast, an organ system with complex ties to sexuality and potential pathology. The adolescent female may present with concerns of having too large or too small breasts, breast pain, breast mass, or other issues as noted in this chapter. Concerns that are raised should be addressed with a comprehensive yet sensitive history and physical examination. Pharmacological management is also concerned where appropriate.

References